<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00670774</url>
  </required_header>
  <id_info>
    <org_study_id>07-007208</org_study_id>
    <nct_id>NCT00670774</nct_id>
  </id_info>
  <brief_title>Dosing Regimen of Eculizumab Added to Conventional Treatment in Positive Cross Match Living Donor Kidney Transplant</brief_title>
  <official_title>A Single Center, Open-label Study to Determine the Safety and Efficacy of a Dosing Regimen of Eculizumab Added to Conventional Treatment in the Prevention of Antibody-mediated Rejection (AMR) in Positive Crossmatch Living Donor Kidney Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mark Stegall</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Alexion Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A strongly positive crossmatch has long been considered an absolute contraindication to
      kidney transplantation and most patients with anti-human leukocyte antigen (HLA) antibody
      never were able to receive a kidney transplant. Over the past decade, significant progress
      has been made in overcoming early antibody-mediated renal allograft injury. Our group has
      performed more than 200 such transplants providing the possibility of transplant to
      previously untransplantable patients. Despite our best efforts, transplantation in these
      patients is still complicated by a high rate of acute humoral rejection (AHR).

      Patients included in this study will be those who have demonstrable anti-HLA antibody
      specific for their living donor. It is our hypothesis that blockade of terminal complement
      activation at the time of transplant in combination with our current protocols will reduce
      the incidence of AHR in patients with anti-donor HLA antibody.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The eculizumab dosing regimen was modified from that used in the treatment of paroxysmal
      nocturnal hemoglobinuria and consisted of 1200 mg immediately prior to transplantation, 600
      mg on postoperative day 1, and 600 mg weekly thereafter for 4 weeks. At week 4, assessment of
      DSA levels was performed. Eculizumab was discontinued in patients whose DSA had significantly
      decreased (B flow crossmatch channel shift&lt;200). In patients with persistently high DSA and
      thus believed to have continued high risk for AMR, eculizumab treatment continued (1200 mg
      week 5, and then every 2 weeks). Another DSA assessment was performed at week 9 and
      eculizumab was discontinued if the B flow crossmatch channel shift was &lt;200.

      The eculizumab group were compared to a historical control group consisting of consecutive
      transplants between 1/1/2005 and 1/10/2017 who met the inclusion criteria. The historical
      control group had been treated with a similar plasma exchange based protocol without
      eculizumab.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2008</start_date>
  <completion_date type="Actual">August 2017</completion_date>
  <primary_completion_date type="Actual">May 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects With Antibody-Mediated Rejection (AMR) in the First 3 Months After Living Donor Kidney Transplantation</measure>
    <time_frame>up to 3 months</time_frame>
    <description>AMR can cause acute graft loss or shorten allograft survival. Renal allograft biopsies were obtained percutaneously using ultrasound guidance processed for light microscopy and immunofluorescence for peritubular capillary staining for C4d. All biopsies were reviewed by a pathologist in a blinded fashion. AMR was diagnosed using standard Banff criteria in combination with graft dysfunction (increase in serum creatinine &gt;/=0.3 mg/dL over nadir.)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Developing High DSA Levels at Less Than or Equal to 3 Months</measure>
    <time_frame>3 months</time_frame>
    <description>High DSA levels were defined as B flow cross match channel shift &gt;350 at any time point in the first 3 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Requiring Splenectomy</measure>
    <time_frame>1 year</time_frame>
    <description>A splenectomy is a surgical operation involving removal of the spleen. Splenectomy was performed for severe AMR in the setting of a rising serum creatinine (usually &gt;2.0) and a rising serum DSA level despite daily plasma exchange treatments.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft Dysfunction in First Month Post Transplant</measure>
    <time_frame>1 month</time_frame>
    <description>(Maximum serum creatinine-nadir serum creatinine)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Follow-up</measure>
    <time_frame>up to 15 months</time_frame>
    <description>Following the completion of dosing, subjects were to return for follow-up visits at 3 and 6 months post transplant to obtain biopsies and collect follow-up data. Subjects who continued the drug for 12 months were to receive their final assessment at 15 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Graft Survival at One Year</measure>
    <time_frame>1 year</time_frame>
    <description>Graft survival means the kidney has not been rejected by the body.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Receiving Posttransplant Plasma Exchange (PE)</measure>
    <time_frame>up to one year</time_frame>
    <description>Plasma exchange is needed when there is poor kidney functioning, and donor specific alloantibody (DSA) is high</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transplant Glomerulopathy Incidence at One Year</measure>
    <time_frame>1 year</time_frame>
    <description>Transplant glomerulopathy is a morphologic lesion of renal allografts that is characterized histologically by duplication and/or multilayering of the glomerular basement membrane. It is widely accepted as a manifestation of chronic antibody-mediated rejection (AMR). This is determined by histology.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Kidney Transplant</condition>
  <arm_group>
    <arm_group_label>Eculizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients received eculizumab intravenously according to details provided in the intervention description.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eculizumab</intervention_name>
    <description>Patients will be given 1200 mg of eculizumab intravenously over 30 minutes, 1 hour prior to surgery.
Patients will be given 900 mg of eculizumab on Day 1 post-transplant.
Patients will then be given 900 mg of eculizumab weekly through 4 weeks post-transplant
At week 4, patients will be assessed for B cell flow cytometry cross match (FCXM). Patients with B cell FCXM less than 200 will stop eculizumab treatment. Patients with B cell FCXM greater than or equal to 200 will continue eculizumab treatment every 14 days from week 5 through week 9. The dose will be increased to 1200 mg and dosing will now be every 2 weeks instead of weekly. Similar &quot;discontinuation assessments&quot; will be performed at week 9, 26, 39 and 52.
In addition, eculizumab 600 mg will be administered immediately after each plasmapheresis (PP) and immediately after any fresh frozen plasma (FFP) that is given post-transplant during the treatment period</description>
    <arm_group_label>Eculizumab</arm_group_label>
    <other_name>Soliris</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18 years of age

          2. Has end stage renal disease (ESRD) and is to receive a kidney transplant from a living
             donor (LD) to whom he/she has either:

               1. A positive crossmatch requiring pretransplant desensitization (defined as a
                  positive T-cell FCXM of greater than or equal to 300 but less than 450 prior to
                  desensitization, or as a positive B-cell FCXM of &gt; 300 but &lt; 450 prior to
                  desensitization with demonstrable Class II donor specific alloantibody (DSA) on
                  solid-phase assays). Subsequent to desensitization, patient must have, at the
                  time of transplant, a T-cell and B-cell FCXM less than 300; or

               2. A positive crossmatch not requiring desensitization (defined as FCXM between 200
                  and 299)

          3. Willing to comply with the protocol

          4. Females of child-bearing potential must have a negative pregnancy test (serum Î²-HCG)
             and sexually active females must agree to use a reliable and medically approved method
             of contraception

          5. Willing and able to give written informed consent

          6. Vaccinated against Neisseria meningitides (quadrivalent vaccine), Pneumococcus or H.
             influenzae at least two weeks prior to beginning desensitization

        Exclusion Criteria:

          1. Unstable cardiovascular condition

          2. Previous splenectomy

          3. Active bacterial or other infection which is clinically significant in the opinion of
             the investigator

          4. Known or suspected hereditary complement deficiency

          5. Participation in any other investigational drug study or was exposed to an
             investigational drug or device within 30 days of randomization

          6. Pregnant, breast-feeding, or intending to conceive during the course of the study,
             including the two month follow-up period after drug discontinuation

          7. Known hypersensitivity to the treatment drug or any of its excipients

          8. History of illicit drug use or alcohol abuse within the previous year

          9. History of meningococcal disease

         10. Medical condition that, in the opinion of the investigator, might interfere with the
             patient's participation in the study, pose an added risk for the patient, or confound
             the assessment of the patient (e.g. severe cardiovascular or pulmonary disease)

         11. Previously been enrolled in this trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark D. Stegall, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicaltrials.mayo.edu</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <results_reference>
    <citation>Stegall MD, Diwan T, Raghavaiah S, Cornell LD, Burns J, Dean PG, Cosio FG, Gandhi MJ, Kremers W, Gloor JM. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant. 2011 Nov;11(11):2405-13. doi: 10.1111/j.1600-6143.2011.03757.x. Epub 2011 Sep 22. Erratum in: Am J Transplant. 2013 Jan;13(1):241.</citation>
    <PMID>21942930</PMID>
  </results_reference>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>April 28, 2008</study_first_submitted>
  <study_first_submitted_qc>April 30, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 2, 2008</study_first_posted>
  <results_first_submitted>May 23, 2018</results_first_submitted>
  <results_first_submitted_qc>May 23, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">June 26, 2018</results_first_posted>
  <last_update_submitted>May 23, 2018</last_update_submitted>
  <last_update_submitted_qc>May 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Mark Stegall</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Kidney</keyword>
  <keyword>Transplant</keyword>
  <keyword>donor</keyword>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 9, 2011</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/74/NCT00670774/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Consecutive kidney transplant patients recruited between 1/6/2008 and 1/8/2010 were recruited at Mayo Clinic in Rochester, Minnesota.</recruitment_details>
      <pre_assignment_details>31 subjects signed informed consent, but 5 patients were screen failures and did not start the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Eculizumab</title>
          <description>Patients received eculizumab intravenously according to details provided in the intervention description.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Only subjects who received eculizumab and were transplanted were included in the baseline characteristics.</population>
      <group_list>
        <group group_id="B1">
          <title>Eculizumab</title>
          <description>Patients received eculizumab intravenously according to details provided in the intervention description.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="26"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.6" spread="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Caucasian white</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Donor Specific Alloantibody</title>
          <description>The presence and amount of donor specific alloantibody (DSA) was assessed using cell-based T- and B-flow cytometric crossmatch channel shift. The channel shift is the observed number of channels (raw fluorescence) above the negative control. The units for DSA are mean channel fluorescence (MCF) shifts from negative control (MCF shift from NC).</description>
          <units>MCF shift from NC</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="330" spread="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Antibody-Mediated Rejection (AMR) in the First 3 Months After Living Donor Kidney Transplantation</title>
        <description>AMR can cause acute graft loss or shorten allograft survival. Renal allograft biopsies were obtained percutaneously using ultrasound guidance processed for light microscopy and immunofluorescence for peritubular capillary staining for C4d. All biopsies were reviewed by a pathologist in a blinded fashion. AMR was diagnosed using standard Banff criteria in combination with graft dysfunction (increase in serum creatinine &gt;/=0.3 mg/dL over nadir.)</description>
        <time_frame>up to 3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Eculizumab</title>
            <description>Patients received eculizumab intravenously according to details provided in the intervention description.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Antibody-Mediated Rejection (AMR) in the First 3 Months After Living Donor Kidney Transplantation</title>
          <description>AMR can cause acute graft loss or shorten allograft survival. Renal allograft biopsies were obtained percutaneously using ultrasound guidance processed for light microscopy and immunofluorescence for peritubular capillary staining for C4d. All biopsies were reviewed by a pathologist in a blinded fashion. AMR was diagnosed using standard Banff criteria in combination with graft dysfunction (increase in serum creatinine &gt;/=0.3 mg/dL over nadir.)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Developing High DSA Levels at Less Than or Equal to 3 Months</title>
        <description>High DSA levels were defined as B flow cross match channel shift &gt;350 at any time point in the first 3 months.</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Eculizumab</title>
            <description>Patients received eculizumab intravenously according to details provided in the intervention description.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Developing High DSA Levels at Less Than or Equal to 3 Months</title>
          <description>High DSA levels were defined as B flow cross match channel shift &gt;350 at any time point in the first 3 months.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Requiring Splenectomy</title>
        <description>A splenectomy is a surgical operation involving removal of the spleen. Splenectomy was performed for severe AMR in the setting of a rising serum creatinine (usually &gt;2.0) and a rising serum DSA level despite daily plasma exchange treatments.</description>
        <time_frame>1 year</time_frame>
        <population>10 subjects discontinued early (&lt;1 year) according to protocol because they had a B flow cytometric crossmatch (BFMX) &lt;200.</population>
        <group_list>
          <group group_id="O1">
            <title>Eculizumab</title>
            <description>Patients received eculizumab intravenously according to details provided in the intervention description.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Requiring Splenectomy</title>
          <description>A splenectomy is a surgical operation involving removal of the spleen. Splenectomy was performed for severe AMR in the setting of a rising serum creatinine (usually &gt;2.0) and a rising serum DSA level despite daily plasma exchange treatments.</description>
          <population>10 subjects discontinued early (&lt;1 year) according to protocol because they had a B flow cytometric crossmatch (BFMX) &lt;200.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Graft Dysfunction in First Month Post Transplant</title>
        <description>(Maximum serum creatinine-nadir serum creatinine)</description>
        <time_frame>1 month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Eculizumab</title>
            <description>Patients received eculizumab intravenously according to details provided in the intervention description.</description>
          </group>
        </group_list>
        <measure>
          <title>Graft Dysfunction in First Month Post Transplant</title>
          <description>(Maximum serum creatinine-nadir serum creatinine)</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.45" spread="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Length of Follow-up</title>
        <description>Following the completion of dosing, subjects were to return for follow-up visits at 3 and 6 months post transplant to obtain biopsies and collect follow-up data. Subjects who continued the drug for 12 months were to receive their final assessment at 15 months.</description>
        <time_frame>up to 15 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Eculizumab</title>
            <description>Patients received eculizumab intravenously according to details provided in the intervention description.</description>
          </group>
        </group_list>
        <measure>
          <title>Length of Follow-up</title>
          <description>Following the completion of dosing, subjects were to return for follow-up visits at 3 and 6 months post transplant to obtain biopsies and collect follow-up data. Subjects who continued the drug for 12 months were to receive their final assessment at 15 months.</description>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.9" spread="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Graft Survival at One Year</title>
        <description>Graft survival means the kidney has not been rejected by the body.</description>
        <time_frame>1 year</time_frame>
        <population>10 subjects discontinued early (&lt;1 year) according to protocol because they had a B flow cytometric crossmatch (BFMX) &lt;200.</population>
        <group_list>
          <group group_id="O1">
            <title>Eculizumab</title>
            <description>Patients received eculizumab intravenously according to details provided in the intervention description.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Graft Survival at One Year</title>
          <description>Graft survival means the kidney has not been rejected by the body.</description>
          <population>10 subjects discontinued early (&lt;1 year) according to protocol because they had a B flow cytometric crossmatch (BFMX) &lt;200.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Receiving Posttransplant Plasma Exchange (PE)</title>
        <description>Plasma exchange is needed when there is poor kidney functioning, and donor specific alloantibody (DSA) is high</description>
        <time_frame>up to one year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Eculizumab</title>
            <description>Patients received eculizumab intravenously according to details provided in the intervention description.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Receiving Posttransplant Plasma Exchange (PE)</title>
          <description>Plasma exchange is needed when there is poor kidney functioning, and donor specific alloantibody (DSA) is high</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Transplant Glomerulopathy Incidence at One Year</title>
        <description>Transplant glomerulopathy is a morphologic lesion of renal allografts that is characterized histologically by duplication and/or multilayering of the glomerular basement membrane. It is widely accepted as a manifestation of chronic antibody-mediated rejection (AMR). This is determined by histology.</description>
        <time_frame>1 year</time_frame>
        <population>10 subjects discontinued early (&lt;1 year) according to protocol because they had a B flow cytometric crossmatch (BFMX) &lt;200. An additional subject did not have a biopsy done at one year.</population>
        <group_list>
          <group group_id="O1">
            <title>Eculizumab</title>
            <description>Patients received eculizumab intravenously according to details provided in the intervention description.</description>
          </group>
        </group_list>
        <measure>
          <title>Transplant Glomerulopathy Incidence at One Year</title>
          <description>Transplant glomerulopathy is a morphologic lesion of renal allografts that is characterized histologically by duplication and/or multilayering of the glomerular basement membrane. It is widely accepted as a manifestation of chronic antibody-mediated rejection (AMR). This is determined by histology.</description>
          <population>10 subjects discontinued early (&lt;1 year) according to protocol because they had a B flow cytometric crossmatch (BFMX) &lt;200. An additional subject did not have a biopsy done at one year.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Eculizumab</title>
          <description>Patients received eculizumab intravenously according to details provided in the intervention description.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Dissection of the iliac</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Lymphocele</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Rapid pulse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea and vomiting</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Abdominal pain secondary to constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Tonic-colonic seizure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Tertiary Hyperparathyroidism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Light headed</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Diaphoresis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Small bowel perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Ulnar fracture secondary to a dog bite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated Creatinine</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Cross-connection end-to-end of the segments of the same ureter</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Elevated Creatinine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Pain following kidney biopsy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Acute humoral rejection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Bleeding following kidney biopsy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute dyspnea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Pulmonary blastomycosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Swelling and erythema of left hand</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Mark D. Stegall</name_or_title>
      <organization>Mayo Clinic</organization>
      <phone>507-284-6275</phone>
      <email>Stegall.Mark@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

